Focus: Cellares is a biotechnology company specializing in automated cell therapy manufacturing technology, positioned to enable scalable production of gene and cell therapies. Operating at Series C+ stage with 201-500 employees, the company develops manufacturing infrastructure for the cell therapy sector.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Contracting — net -34 jobs in 30d
1 added, 35 removed. Active reduction in progress.
Cellares operates in a strategically important niche (cell therapy manufacturing automation) but faces near-term revenue headwinds from customer loss and demonstrated layoff activity; suitable for mission-driven technologists willing to tolerate execution risk in exchange for deep specialization.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Cellares
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Cellares's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Demonstrated cost restructuring tied to customer loss is a material red flag; role stability depends on diversifying customer base and maintaining manufacturing partnerships.
Recent peer-reviewed publications with author affiliations at this company